US 11,724,004 B2
Transglutaminase treated products
Yi Chen, Pleasanton, CA (US); Sean Collins, Valley Cottage, NY (US); Li Ting Huang, Branchburg, NJ (US); Eric Stec, Washington, NJ (US); and Hui Xu, Plainsboro, NJ (US)
Assigned to LifeCell Corporation, North Chicago, IL (US)
Filed by LifeCell Corporation, Madison, NJ (US)
Filed on Oct. 6, 2020, as Appl. No. 17/63,863.
Application 17/063,863 is a continuation of application No. 16/546,608, filed on Aug. 21, 2019, granted, now 10,814,033.
Application 16/546,608 is a continuation of application No. 15/882,400, filed on Jan. 29, 2018, granted, now 10,413,634, issued on Sep. 17, 2019.
Claims priority of provisional application 62/452,000, filed on Jan. 30, 2017.
Prior Publication US 2021/0015970 A1, Jan. 21, 2021
Int. Cl. A61L 27/34 (2006.01); A61L 27/24 (2006.01); A61L 27/36 (2006.01); A61L 27/54 (2006.01); A61L 27/56 (2006.01); A61F 2/00 (2006.01); A61L 27/16 (2006.01)
CPC A61L 27/34 (2013.01) [A61F 2/0063 (2013.01); A61L 27/16 (2013.01); A61L 27/24 (2013.01); A61L 27/362 (2013.01); A61L 27/3687 (2013.01); A61L 27/54 (2013.01); A61L 27/56 (2013.01); A61F 2210/0004 (2013.01); A61L 2300/254 (2013.01)] 20 Claims
 
1. A method of treatment, comprising:
selecting a medical device comprising an implant main body portion comprising a collagen-containing tissue matrix having a surface region that has been treated with a transglutaminase coating, and wherein the treated surface region provides at least one of an anti-adhesion or anti-abrasion property to the tissue matrix; and
implanting the medical device into or on an anatomic site.